Calithera Biosciences, a clinical-stage oncology biopharmaceutical company that specializes in targeted therapies for biomarker-specific patient populations, has developed CB-839 and erlotinib, which together reduce glucose and glutamine uptake, for treating patients with EGFR (epidermal growth factor receptor)-mutated stage IV non-small-cell lung cancer [252]. Here, EGFR is linked to non-small cell lung carcinoma.